C-Peptide Induces Chemotaxis of Human CD4-Positive Cells
Involvement of Pertussis Toxin–Sensitive G-Proteins and Phosphoinositide 3-Kinase
- Daniel Walcher1,
- Milos Aleksic1,
- Verena Jerg1,
- Vinzenz Hombach1,
- Arthur Zieske2,
- Satoki Homma2,
- Jack Strong2 and
- Nikolaus Marx1
- 1Department of Internal Medicine II-Cardiology, University of Ulm, Ulm, Germany
- 2Louisiana State University, Health Sciences Center, New Orleans, Louisiana
- Address correspondence and reprint requests to Nikolaus Marx, MD, Department of Internal Medicine II-Cardiology, University of Ulm, Robert-Koch-Strasse 8, D-89081 Ulm, Germany. E-mail: nikolaus.marx{at}medizin.uni-ulm.de
Abstract
Increased levels of C-peptide, a cleavage product of proinsulin, circulate in patients with insulin resistance and early type 2 diabetes, a high-risk population for the development of a diffuse and extensive pattern of arteriosclerosis. The present study examined the effect of C-peptide on CD4+ lymphocyte migration, an important process in early atherogenesis. C-peptide stimulated CD4+ cell chemotaxis in a concentration-dependent manner. This process involves pertussis toxin–sensitive G-proteins as well as activation of phosphoinositide 3-kinase (PI 3-K). Biochemical analysis showed that C-peptide induced recruitment of PI 3-K to the cell membrane as well as PI 3-K activation in human CD4+ cells. In addition, antidiabetic peroxisome proliferator–activated receptor γ–activating thiazolidinediones inhibited C-peptide–induced CD4+ cell chemotaxis as well as PI 3-Kγ activation. Finally, immunofluorescence staining of thoracic artery specimen of diabetic patients showed intimal CD4+ cells in areas with C-peptide deposition. Thus, C-peptide might deposit in the arterial intima in diabetic patients during early atherogenesis and subsequently attract CD4+ cells to migrate into the vessel wall.
- PI 3-K, phosphoinositide 3-kinase
- PPAR, peroxisome proliferator–activated receptor
- TZD, thiazolidinedione
Footnotes
-
D.W. and M.A. contributed equally to this work.
-
- Accepted March 29, 2004.
- Received September 4, 2003.
- DIABETES














